Methods And Systems For Improved Pharmaceutical Intervention In Coagulation Control

• US 20110251834A1
• Filed: 10/15/2009
• Published: 10/13/2011
• Est. Priority Date: 10/20/2008
• Status: Active Grant

• Current Assignee: Michael Fearon, Paul T. Wegener
• Original Assignee: Michael Fearon, Paul T. Wegener
• Inventors: Fearon, Michael, Wegener, Paul T.
• Granted Patent: US 8,688,416 B2
• Time in Patent Office: Days
• US Class Current: 703/2
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Contemplated methods and devices for coagulation control allow to establish a more constant dosage of required medication and to quantify/take into account patient-specific sensitivity to warfarin and Vitamin K by using logit (1/INR) as the dependent variable to so stabilize the variance across all values of INR. Moreover, it should be noted that such use simplifies the relation between INR and dose of coumarins or Vitamin K and reduces the number of parameters to be estimated for each patient.

Claims

1. A method of assisting anticoagulant therapy in a patient, comprising:

providing a coagulation calculator;

configuring the coagulation calculator to perform a calculation operation where logit (1/INR)=−

log (INR−

1) is used as a dependent variable and to produce a result based on the calculation operation; and

further configuring the coagulation calculator to allow presentation of a result of the calculation operation.

2. The method of claim 1 wherein the calculation operation is a calculation of a target dosage of an anticoagulant to achieve a desired INR value.

3. The method of claim 2 wherein the target dosage of the anticoagulant is calculated according to equation (I)

log (INR−

1)=log (I*−

1)+b(w−

w*) 

 

(I)

wherein INR is the INR measured in the patient, I* is the desired INR for the patient, b is a patient-specific constant that describes a patient specific response to the anticoagulant, w* is the target dosage, and w is the effective dose of the anticoagulant.

4. The method of claim 3 wherein the patient has been taking a same daily dose, w′

, of warfarin so long that the effective dose is equal to w′

.

5. The method of claim 3 wherein w is estimated from the patient'"'"'s dosage history.

6. The method of claim 3 wherein b is estimated from the values of w and the patient'"'"'s corresponding INR.

7. The method of claim 2 wherein the target dosage of the anticoagulant is calculated according to equation (II)

log (INR−

1)=log (I*−

1)+b(w−

w*)−

c log (K/K0) 

 

(II)

wherein INR is the INR measured in the patient, I* is the desired INR for the patient, b is a patient-specific constant that describes a patient specific response to the anticoagulant, w* is the target dosage, w is the effective dose of the anticoagulant, c is a patient-specific parameter, K is effective uptake of Vitamin K by the patient, and K0 is average uptake of Vitamin K by the patient.

8. The method of claim 7 further comprising a step of calculating a supplemental uptake of vitamin K to achieve a desired INR value.

9. The method of claim 8 wherein the supplemental uptake rK0 is calculated according to equation (III)

r=exp[b(w1−

w*)/c]−

1 

 

(III)

wherein w1 is an anticoagulant dosage that is greater than the target dosage.

10. The method of claim 2 wherein anticoagulant therapy is initiated in the patient and wherein the calculation of the target dosage of the anticoagulant is calculated according to equation (IV)

w*=w−

(1/b) log [(INR−

1)/(I*−

1)] 

 

(IV)

wherein INR is a first INR value measured in the patient, I* is the desired INR for the patient, b is an a priori value of sensitivity to the anticoagulant applicable to the patient'"'"'s known characteristics, wherein w* is the target dosage, and wherein w is an effective dose based on an a priori value of half-stabilization time applicable to the patient'"'"'s known characteristics.

11. A coagulation calculator, comprising:

a memory element functionally coupled to a processor, an input module, and an output module;

wherein the memory element stores software instructions to perform a calculation operation in which logit (1/INR)=−

log (INR−

1) is used as a dependent variable;

wherein the processor is configured to execute the software instructions to so produce a result; and

wherein the output module is configured to allow presentation of the result.

12. The coagulation calculator of claim 11 wherein the calculation operation is a calculation of a target dosage of an anticoagulant to achieve a desired INR value.

13. The coagulation calculator of claim 12 wherein the target dosage of the anticoagulant is calculated according to equation (I)

log (INR−

1)=log (I*'"'"'11)+b(w−

w*) 

 

(I)

wherein INR is the INR measured in the patient, I* is the desired INR for the patient, b is a patient-specific constant that describes a patient specific response to the anticoagulant, w* is the target dosage, and w is the effective dose of the anticoagulant.

14. The coagulation calculator of claim 12 wherein the target dosage of the anticoagulant is calculated according to equation (II)

log (INR−

1)=log (I*−

1)+b(w−

w*)−

c log (K/K0) 

 

(II)

wherein INR is the INR measured in the patient, I* is the desired INR for the patient, b is a patient-specific constant that describes a patient specific response to the anticoagulant, w* is the target dosage, w is the effective dose of the anticoagulant, c is a patient-specific parameter, K is effective uptake of Vitamin K by the patient, and K0 is average uptake of Vitamin K by the patient.

15. The coagulation calculator of claim 12 wherein anticoagulant therapy is initiated in the patient and wherein the calculation of the target dosage of the anticoagulant is calculated according to equation (IV)

w*=w−

(1/b) log [(INR−

1)/(I*−

1)] 

 

(IV)

wherein INR is a first INR value measured in the patient, I* is the desired INR for the patient, b is an a priori value of sensitivity to the anticoagulant applicable to the patient'"'"'s known characteristics, wherein w* is the target dosage, and wherein w is an effective dose based on an a priori value of half-stabilization time applicable to the patient'"'"'s known characteristics.